uric acid has been researched along with Hyperlipoproteinemia in 34 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fenofibrate, a phenoxyacid derivative, given at daily dose of 300mg during 1 year following a single blind design, lowered significantly serum triglycerides and total cholesterol in patients various types of hyperlipoproteinemias (IIa, IV, V), fibrate significantly reduced plasma uric acid." | 9.05 | Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. ( Desager, JP; Harvengt, C; Heller, F, 1980) |
| " In the study reported, the effect of 2-acetamidoethyl-(p-chlorophenyl)-(m-trifluoro-methylphenoxy)-acetate (halofenate) was investigated in 14 patients suffering from hyperlipoproteinemia type IV and hyperuricemia." | 9.04 | [Effect of halofenate on triglyceride and uric acid levels, coagulation and platelet behaviour in patients with hyperlipoproteinemia type IV and hyperuricemia (author's transl)]. ( Hehl, FJ; Kuntzen, O; Walter, E; Zimmermann, R, 1978) |
| " In type IIa etofylline clofibrate shows a good effect on total cholesterol and on the cholesterol fractions, both with regard to the collective treated and to the low dosage of 750 mg/d etofylline clofibrate compared to the usual dosage of 1500 mg clofibrate." | 5.26 | [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)]. ( Hausmann, L; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980) |
| "Fenofibrate is a potent hypolipemic agent, widely used in patients with mild to severe renal failure in whom hyperlipoproteinemia is frequent." | 5.09 | [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency]. ( Achard, JM; el Esper, N; Fournier, A; Hottelart, C; Pruna, A, 1999) |
| "Fenofibrate, a phenoxyacid derivative, given at daily dose of 300mg during 1 year following a single blind design, lowered significantly serum triglycerides and total cholesterol in patients various types of hyperlipoproteinemias (IIa, IV, V), fibrate significantly reduced plasma uric acid." | 5.05 | Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. ( Desager, JP; Harvengt, C; Heller, F, 1980) |
| " In the study reported, the effect of 2-acetamidoethyl-(p-chlorophenyl)-(m-trifluoro-methylphenoxy)-acetate (halofenate) was investigated in 14 patients suffering from hyperlipoproteinemia type IV and hyperuricemia." | 5.04 | [Effect of halofenate on triglyceride and uric acid levels, coagulation and platelet behaviour in patients with hyperlipoproteinemia type IV and hyperuricemia (author's transl)]. ( Hehl, FJ; Kuntzen, O; Walter, E; Zimmermann, R, 1978) |
| "Twenty-two patients suffering from hyperlipidemia and receiving therapy consisting of a lipid-lowering diet and clofibrate (1 g X 2) were in addition given colestipol hydrochloride (5 g X 3) (Colestid, Upjohn) in a randomized, cross-over study for 2 periods of 6 weeks." | 2.65 | The effects of colestipol when combined with clofibrate in the treatment of severe hyperlipidemia. Short-term and long-term studies. ( Boberg, J; Hellsing, K; Lithell, H; Vessby, B, 1980) |
| "Patients with NIDDM had 11% increase of high density lipoprotein-cholesterol (HDL-C) level at the end of the first, and 18% increase at the end of the second month, while patients with primary hyperlipoproteinaemia did not change significantly." | 1.30 | Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia. ( Balogh, Z; Boda, J; Kárpáti, L; Kovács, P; Leövey, A; Paragh, G; Szabó, J, 1997) |
| " In type IIa etofylline clofibrate shows a good effect on total cholesterol and on the cholesterol fractions, both with regard to the collective treated and to the low dosage of 750 mg/d etofylline clofibrate compared to the usual dosage of 1500 mg clofibrate." | 1.26 | [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)]. ( Hausmann, L; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (85.29) | 18.7374 |
| 1990's | 3 (8.82) | 18.2507 |
| 2000's | 1 (2.94) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, X | 1 |
| Wang, T | 1 |
| Huang, S | 1 |
| Zeng, P | 1 |
| Kaffarnik, H | 1 |
| Schneider, J | 2 |
| Schubotz, R | 2 |
| Zöfel, P | 1 |
| Hausmann, L | 2 |
| Goebel, KM | 1 |
| Barats, IS | 2 |
| Makarova, VIu | 1 |
| Dumas, JR | 1 |
| Krajnc, I | 1 |
| Kerum, G | 1 |
| Muggeo, M | 1 |
| Calabrò, A | 1 |
| Businaro, V | 1 |
| Moghetti, P | 1 |
| Padovan, D | 1 |
| Crepaldi, G | 1 |
| Reinhardt, K | 1 |
| Wagner, M | 1 |
| Lithell, H | 1 |
| Vessby, B | 1 |
| Boberg, J | 1 |
| Hellsing, K | 1 |
| Haller, H | 1 |
| Jaross, W | 1 |
| Hanefeld, M | 1 |
| Fiegel, G | 1 |
| Heidelmann, G | 2 |
| Thiele, P | 3 |
| Schröder, HE | 4 |
| Mühlfellner, G | 1 |
| Mühlfellner, O | 1 |
| Lohse, R | 1 |
| Böhm, WD | 1 |
| Harvengt, C | 1 |
| Heller, F | 1 |
| Desager, JP | 1 |
| Grabner, W | 1 |
| Worlicek, H | 1 |
| Beenken, O | 1 |
| Kopperschläger, G | 1 |
| Otto, W | 1 |
| Häntzschel, H | 1 |
| Pietruschka, WD | 1 |
| Weinhold, D | 1 |
| Schwartzkopff, W | 1 |
| Schilling, A | 1 |
| Calder, D | 1 |
| Schneider, H | 2 |
| Ziegelasch, HJ | 2 |
| Eggenberger, M | 1 |
| Paragh, G | 1 |
| Balogh, Z | 1 |
| Boda, J | 1 |
| Kovács, P | 1 |
| Kárpáti, L | 1 |
| Szabó, J | 1 |
| Leövey, A | 1 |
| Hottelart, C | 1 |
| el Esper, N | 1 |
| Achard, JM | 1 |
| Pruna, A | 1 |
| Fournier, A | 1 |
| Rohrbach, JM | 1 |
| Kleiser, N | 1 |
| Kaufmann-Fechner, J | 1 |
| Lisch, W | 1 |
| Kuntzen, O | 1 |
| Hehl, FJ | 1 |
| Walter, E | 1 |
| Zimmermann, R | 1 |
| de Oliveira, JM | 1 |
| Schwandt, P | 1 |
| Richter, WO | 1 |
| Kullich, W | 1 |
| Ulreich, A | 1 |
| Klein, G | 1 |
| Seidel, D | 1 |
| Cremer, P | 1 |
| Segers, AM | 1 |
| de Forteza, IE | 1 |
| Conforti, FY | 1 |
| Abulafia, J | 1 |
| Wallace, RB | 1 |
| Pomrehn, P | 1 |
| Heiss, G | 1 |
| Chambless, LE | 1 |
| Johnson, N | 1 |
| Patten, R | 1 |
| Lippel, K | 1 |
| Rifkind, BM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00005128] | 0 participants | Observational | 1972-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for uric acid and Hyperlipoproteinemia
| Article | Year |
|---|---|
Complete destruction of both femoral heads following idiopathic necrosis of the femoral heads in a diabetic patient with hyperuricemia and hyperlipoproteinemia.
Topics: Aged; Angiography; Diabetes Complications; Femur Head Necrosis; Gout; Heel; Hip; Humans; Hyperlipopr | 1980 |
[Alcohol and lipid metabolism].
Topics: Alcohol Oxidoreductases; Alcoholism; Anemia, Hemolytic; Ethanol; Fatty Acids, Nonesterified; Humans; | 1981 |
[Hypertension, Type II diabetes mellitus and macroangiopathy: risk factors and their association].
Topics: Albuminuria; Alcohol Drinking; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Exercise; Female; H | 1994 |
[Corneal ring opacity (Ascher ring)--a case report].
Topics: Cornea; Corneal Opacity; Diagnosis, Differential; Humans; Hyperlipoproteinemias; Male; Middle Aged; | 2001 |
[Genetic metabolic defects in adults].
Topics: Arteriosclerosis; Gout; Humans; Hyperlipoproteinemias; Phenotype; Risk Factors; Uric Acid | 1989 |
5 trials available for uric acid and Hyperlipoproteinemia
| Article | Year |
|---|---|
The effects of colestipol when combined with clofibrate in the treatment of severe hyperlipidemia. Short-term and long-term studies.
Topics: Alkaline Phosphatase; Cholesterol; Clofibrate; Colestipol; Drug Therapy, Combination; Female; Humans | 1980 |
[Therapeutic effect of etofyllinclofibrate in disordered lipid and uric acid metabolism].
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Clofibrate; Female; Humans; Hy | 1982 |
Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias.
Topics: Adult; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids; Middle Aged; Propio | 1980 |
[Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency].
Topics: Aged; Creatinine; Cross-Over Studies; Female; Fenofibrate; Glomerular Filtration Rate; Humans; Hyper | 1999 |
[Effect of halofenate on triglyceride and uric acid levels, coagulation and platelet behaviour in patients with hyperlipoproteinemia type IV and hyperuricemia (author's transl)].
Topics: Adult; Blood Coagulation; Cholesterol; Double-Blind Method; Glycolates; Halofenate; Humans; Hyperlip | 1978 |
24 other studies available for uric acid and Hyperlipoproteinemia
| Article | Year |
|---|---|
Evaluation of the causal effects of blood lipid levels on gout with summary level GWAS data: two-sample Mendelian randomization and mediation analysis.
Topics: Age Factors; Causality; Cholesterol; Dyslipidemias; Genome-Wide Association Study; Gout; Humans; Hyp | 2021 |
Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Creatine Kinase; Female; gamma-Glutamyltransfe | 1980 |
[Hyperuricemia in ischemic heart disease].
Topics: Adult; Body Weight; Coronary Disease; Diuretics; Gout; Humans; Hyperlipoproteinemias; Hypertension; | 1984 |
[State of lipid and purine metabolism in children with a family history of ischemic heart disease].
Topics: Adolescent; Adult; Child; Child, Preschool; Coronary Disease; Humans; Hyperlipoproteinemias; Infant; | 1984 |
[Protein overload, hyperucemia, gout].
Topics: Adult; Diet; Female; Gout; Humans; Hyperlipoproteinemias; Male; Middle Aged; Uric Acid | 1983 |
[Association of risk factors in patients with hyperuricemia].
Topics: Blood Glucose; Body Weight; Female; Humans; Hyperlipoproteinemias; Lipids; Male; Uric Acid | 1983 |
[Correlation of metabolic and hemorrheological parameters in diabetes and hyperlipidemia].
Topics: Blood Viscosity; Cholesterol; Cholesterol, HDL; Diabetes Mellitus; Diabetic Angiopathies; Erythrocyt | 1983 |
[Extraarticular diseases and findings in gout].
Topics: Arteriosclerosis; Diabetes Complications; Female; Gout; Humans; Hyperlipoproteinemias; Hypertension; | 1982 |
[Prognosis for disorders of purine metabolism].
Topics: Age Factors; Arterial Occlusive Diseases; Diabetes Mellitus; Germany, East; Gout; Humans; Hyperlipop | 1982 |
[Prevention and therapy of disorders of purine metabolism].
Topics: Arteriosclerosis; Diabetes Mellitus; Gout; Gout Suppressants; Humans; Hyperlipoproteinemias; Metabol | 1982 |
[Dyslipoproteinemia and hyperuricemia in podagra and urinary calculi].
Topics: Adult; Arteriosclerosis; Cholesterol; Foot Diseases; Gout; Humans; Hyperlipoproteinemias; Hypolipopr | 1982 |
[On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
Topics: Cholesterol; Clofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids; Lipoproteins; | 1980 |
[Incidence of metabolic disorders in patients with recurrent urinary calculi].
Topics: Adult; Aged; Calcium Oxalate; Creatinine; Diabetes Complications; Electrolytes; Female; Humans; Hydr | 1981 |
[The relation between gout and diabetes mellitus].
Topics: Blood Glucose; Diabetes Complications; Diabetes Mellitus; Gout; Humans; Hyperlipoproteinemias; Metab | 1981 |
[Comparative biochemical studies in asymptomatic hyperuricemia and manifest gout with special reference to renal change].
Topics: Adolescent; Adult; Creatinine; Electrophoresis, Polyacrylamide Gel; Gout; Humans; Hyperlipoproteinem | 1981 |
[Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
Topics: Blood Glucose; Cholesterol; Clofibrate; Creatinine; Delayed-Action Preparations; Humans; Hyperlipopr | 1980 |
[Associated cardiovascular factors of risk in borderline-diabetes (author's transl)].
Topics: Adult; Aged; Cholesterol; Diabetes Complications; Female; Glucose Tolerance Test; Humans; Hyperlipop | 1980 |
Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia.
Topics: Apolipoprotein A-I; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; | 1997 |
[The cardiovascular risk profile of the borderline diabetic].
Topics: Adult; Aged; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Humans; Hypercholest | 1979 |
[Coronary risk factors].
Topics: Coronary Disease; Diabetes Complications; Diet; Female; Humans; Hypercholesterolemia; Hyperlipoprote | 1979 |
[Hyperlipoproteinemia in primary gout and asymptomatic hyperuricemia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cholesterol; Creatinine; Gout; Humans; Hyperlipoproteine | 1988 |
Influence of known risk factors on the lipoprotein profile.
Topics: Adult; Alcohol Drinking; Blood Glucose; Body Weight; Humans; Hyperlipoproteinemias; Hypolipoproteine | 1986 |
[Cellulite].
Topics: Adipose Tissue; Carbohydrate Metabolism; Cellulitis; Cholesterol; Female; Galactorrhea; Humans; Hype | 1985 |
Alterations in clinical chemistry levels associated with the dyslipoproteinemias. The Lipid Research Clinics Program Prevalence Study.
Topics: Adult; Blood Glucose; Creatinine; Diabetes Mellitus; Dysgammaglobulinemia; Female; Humans; Hyperlipo | 1986 |